Chinese Pharmacopoeia 2010 Edition To Raise Standards
This article was originally published in PharmAsia News
Executive Summary
Chinese Pharmacopoeia, the gold standard for medicine in China, has begun revising its contents. The 2010 edition will extend the record of chemical pharmaceuticals and TCM, adjust the standards of pharmaceutical technology and prepare a catalog of newly added drugs. The revised draft will be completed before the end of 2008. The pharmaceutical industry subscribes to the standards in Chinese Pharmacopoeia as the minimum basis for the quality of all drugs and production technology. With the Chinese authority's stricter supervision of adverse drug reactions, the revision is set to raise the standards for drug quality. (Click here for more - Chinese Language)
You may also be interested in...
Revised Pharmacopoeia 2010 Edition Focuses On Standardization
The 9th Chinese Pharmacopoeia Commission, established in 2007, recently held a working meeting to discuss the revision of Chinese Pharmacopoeia 2010 edition (PharmAsia News, Feb. 4, 2008). The new directory will focus on raising the standards of TCM, biochemical drugs and injections. The revision will modify those drugs with weak standards or whose methodology cannot be duplicated, as well as eliminate drugs which are not applicable in clinical practice or which have quality control or potential safety risks. A separate injection drug commission will be in charge of collecting injection data and understanding existing problems based on specific subjects such as TCM, antibiotics and biological products. The commission hopes that suggestions contributed will help conceptualize a basic platform for the field. (Click here for more - Chinese Language)
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.